Company profile: Sareum
1.1 - Company Overview
Company description
- Provider of targeted small molecule therapeutics for cancer and autoimmune diseases, delivering drug candidates for licensing at pre-clinical or early clinical stages. Pipeline includes SDC-1801 and SDC-1802 (TYK2/JAK1 inhibitors) and SRA737 (clinical-stage, oral, selective Chk1 inhibitor).
Products and services
- SRA737: A clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms in oncology applications
- SDC-1802: A targeted TYK2/JAK1 inhibitor being developed for cancer and cancer immunotherapy applications, with plans for licensing at pre-clinical or early clinical trial stages
- SDC-1801: A small molecule TYK2/JAK1 inhibitor engineered for treating autoimmune diseases, with a focus on psoriasis, intended for licensing at pre-clinical or early clinical trial stages
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sareum
MirImmune Bio
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on new and improved cancer immunotherapies, combining immune checkpoint inhibition and cell-based immunotherapies, aiming to achieve long-term survival of cancer patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MirImmune Bio company profile →
Dune Medical
HQ: United States
Website
- Description: Provider of intraoperative, real-time cancer detection devices using proprietary tissue characterization technology, enabling surgeons and radiologists to detect cancer in real time with potential for broad diagnostic and therapeutic applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dune Medical company profile →
Intact Medical
HQ: United States
Website
- Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intact Medical company profile →
CatalYm
HQ: Germany
Website
- Description: Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CatalYm company profile →
IO Biotech
HQ: Denmark
Website
- Description: Provider of immune-modulating cancer therapies built on its T-win technology, activating T cells against tumor and immune-suppressive cells. Offers IO102-IO103 T-win vaccines targeting IDO and PD-L1, used with anti-PD-1 therapy for metastatic melanoma, and runs Phase 2/3 trials with pembrolizumab in melanoma, lung, head and neck, and bladder cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IO Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sareum
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sareum
2.2 - Growth funds investing in similar companies to Sareum
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sareum
4.2 - Public trading comparable groups for Sareum
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →